More weight lost on GLP-1s actually lowers complication risk, ECO data says
Posted by tiredmira in Weight Loss & Metabolic - 7 points, 4 comments.
There's a new ECO 2026 presentation showing that the more weight people lose on GLP-1 meds, the lower their risk of obesity-related complications. Basically a dose-response relationship, which honestly is what you'd hope for but it's good to see it laid out with bigger numbers.
What caught my eye is they're framing it as a continuous thing, not just "did you hit 5% or 10%." For me that tracks, because the appetite suppression and the actual health markers like fasting glucose and blood pressure felt like they kept improving the longer I titrated up, not just at some magic threshold.
I'm a bit skeptical though, since this is an abstract presentation and not a peer-reviewed paper yet. Anyone know if they're stratifying by which GLP-1, or pooling everything together? That matters a lot when comparing tirz vs sema vs the newer ones.
Comments
- quiet_ironman: I’ve noticed the same thing with my own titration – as I went up slowly, my fasting numbers kept creeping down and my blood pressure felt steadier, not just jumping at a 5% loss mark. It’s reassuring to see that trend backed by bigger data, even if it’s still just an abstract. I’m curious too whether they split out tirzepatide versus semaglutide versus the newer agents, because the weight‑loss curves differ enough that the risk‑benefit line might shift. Until the full paper drops I’m taking it a
- busykatie: Yeah the split between tirz and sema is a really, the weight loss curves really do look different and i'd guess the metabolic markers probably do too, but until they actually publish the breakdown we're kinda guessing. It is nice to see them frame it as a continuum though, that matched what i saw in my own numbers as i titrated up gradually.
- tiredmira: Yeah the pooled vs stratified thing bugs me too 😅 If they're lumping sema 15mg in with tirz 15mg the averages get kinda meaningless honestly. The framing as a continuum is what actually sold me on the abstract though, because my glucose numbers kept creeping down week over week even when the scale was being weird. Did your markers keep improving all the way up to your final dose, or did they kind of plateau?
- tiredmira: Yeah same, my fasting glucose kept inching down even between dose steps so I bought the continuous framing right away 😅 And good call on the split between agents, tirz definitely pulls weight off faster for me than sema did so I'd expect the risk curve to move differently too. Basically waiting for the full paper before getting too excited.
Community discussion - research and educational context only. Not medical advice.